Cover Image
Market Research Report

Global Opioid-Induced Constipation Market 2018-2022

Published by TechNavio (Infiniti Research Ltd.) Product code 334065
Published Content info 98 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Opioid-Induced Constipation Market 2018-2022
Published: December 6, 2018 Content info: 98 Pages
Description

About this market:

Rise in incidence of chronic diseases such as arthritis, back pain, and migraine is likely to drive growth in the market. The incidence of chronic pain is increasing across the world, owing to the several reasons, including lifestyle changes, rise in number of injuries, growth in number of surgeries, and painful medical conditions. Technavio's analysts have predicted that the opioid-induced constipation market will register a CAGR of more than 32% by 2022.

Market Overview:

Rise in OIC cases among elderly

Rise in incidences of diseases associated with old age, impaired body functions, and increase in the use of medicines such as antidepressants and anticholinergics have collectively led to high prevalence of constipation among the elderly population. This drives growth in the opioid-induced constipation market.

Use of conventional laxatives for OIC

The use of laxatives for OIC is a major challenge that is reducing sales of approved drugs meant for the treatment of OIC.

For the detailed list of factors that will drive and challenge the growth of the opioid-induced constipation market during the 2018-2022, view our report.

Competitive Landscape:

The market appears to be fragmented and with the presence of several companies including Takeda Pharmaceutical and Merck the competitive environment is quite intense. Factors such as the rise in incidence of chronic diseases such as arthritis, back pain, and migraine and the rise in OIC cases among elderly, will provide considerable growth opportunities to opioid-induced constipation manufactures. AstraZeneca, Bausch Health, Takeda Pharmaceutical, and Merck are some of the major companies covered in this report.

Table of Contents
Product Code: IRTNTR23627

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE ANALYSIS

  • Pipeline analysis

PART 06: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: MARKET SEGMENTATION BY ROUTE OF ADMINISTRATION

  • Segmentation by route of administration
  • Comparison by application
  • Oral - Market size and forecast 2017-2022
  • Parenteral - Market size and forecast 2017-2022
  • Market opportunity by application

PART 09: MARKET SEGMENTATION BY CLASS OF DRUGS

  • Segmentation by class of drugs
  • Peripherally acting mu-opioid receptor antagonist
  • Locally acting chloride channel activator
  • Others

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 14: MARKET TRENDS

  • Rise in incidence of chronic diseases such as arthritis, back pain, and migraine
  • Market dominance by opioid receptor antagonists
  • Introduction of separate diagnostic guidelines for idiopathic or functional constipation and OIC

PART 15: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 16: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Bausch Health
  • Takeda Pharmaceutical
  • Merck

PART 17: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Parent market
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Pipeline molecules for OIC
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2017
  • Exhibit 08: Validation techniques employed for market sizing 2017
  • Exhibit 09: Global - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 10: Global - Year-over-year growth 2018-2022 (%)
  • Exhibit 11: Five forces analysis 2017
  • Exhibit 12: Five forces analysis 2022
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2017
  • Exhibit 19: Route of administration - Market share 2017-2022 (%)
  • Exhibit 20: Comparison by application
  • Exhibit 21: Oral - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 22: Oral route - Year-over-year growth 2018-2022 (%)
  • Exhibit 23: Parenteral - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 24: Parenteral route - Year-over-year growth 2018-2022 (%)
  • Exhibit 25: Market opportunity by application
  • Exhibit 26: Customer landscape
  • Exhibit 27: Global - Market share by geography 2017-2022 (%)
  • Exhibit 28: Regional comparison
  • Exhibit 29: Americas - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 30: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 31: Top 3 countries in Americas
  • Exhibit 32: APAC - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 33: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 34: Top 3 countries in APAC
  • Exhibit 35: EMEA - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 36: EMEA - year-over-year growth 2018-2022 (%)
  • Exhibit 37: Top 3 countries in EMEA
  • Exhibit 38: Market opportunity
  • Exhibit 39: Vendor landscape
  • Exhibit 40: Landscape disruption
  • Exhibit 41: Vendor classification
  • Exhibit 42: Market positioning of vendors
  • Exhibit 43: AstraZeneca overview
  • Exhibit 44: AstraZeneca - Business segments
  • Exhibit 45: AstraZeneca - Organizational developments
  • Exhibit 46: AstraZeneca - Geographic focus
  • Exhibit 47: AstraZeneca - Key offerings
  • Exhibit 48: Bausch Health overview
  • Exhibit 49: Bausch Health - Business segments
  • Exhibit 50: Bausch Health - Organizational developments
  • Exhibit 51: Bausch Health - Geographic focus
  • Exhibit 52: Bausch Health - Segment focus
  • Exhibit 53: Bausch Health - Key offerings
  • Exhibit 54: Takeda Pharmaceutical overview
  • Exhibit 55: Takeda Pharmaceutical - Business segments
  • Exhibit 56: Takeda Pharmaceutical - Organizational developments
  • Exhibit 57: Takeda Pharmaceutical - Geographic focus
  • Exhibit 58: Takeda Pharmaceutical - Key offerings
  • Exhibit 59: Merck overview
  • Exhibit 60: Merck - Business segments
  • Exhibit 61: Merck - Organizational developments
  • Exhibit 62: Merck - Geographic focus
  • Exhibit 63: Merck - Segment focus
  • Exhibit 64: Merck - Key offerings
Back to Top